Chronic lymphocytic leukemia-- or CLL-- is a type of ... but because of the change-- called a mutation-- faulty white blood cells that don't work like they should are made instead.

Watchful waiting, also known as active surveillance, is commonly used in most people with CLL. During watchful waiting, blood work and checkups are typically done every three months to assess for ...

In stage 0 CLL, treatment isn’t usually required. The primary medical approach is watchful waiting. During the watchful ...

Ibrutinib normalizes RBC aggregation in CLL, potentially reducing thrombotic risks by mitigating blood flow complications. Obinutuzumab/venetoclax combination does ...

The molecular mechanisms underlying resistance to therapy in Chronic lymphocytic leukemia (CLL) remain to be explored. Here, the authors perform multi-omics analysis in a mouse model of ibrutinib ...

Genome studies of chronic lymphocytic leukemia (CLL) have revealed the remarkable subclonal heterogeneity of the tumors, but the clinical implications of this phenomenon are not well known.

Chronic lymphocytic leukemia (CLL) tends to have a better outlook ... low risk (stage 0) abnormal increase of lymphocytes, a type of white blood cell, in your blood and bone marrow intermediate ...

Chronic lymphocytic leukemia (CLL) is the most common type of adult leukemia in the United States. Leukemia is a group of cancers that develop in blood cells. CLL develops in a type of white blood ...

CLL refers to cancer of the blood and bone marrow ... These approaches may work well for some, but their effectiveness can vary from person to person. Exercise may help increase energy levels ...

Treatment for CLL continues to change. Doctors are using newer targeted cancer drugs ... Some people might have stem cells from donated umbilical cord blood. But this is not as commonly used. The ...

The study enrolled 523 patients with untreated CLL, randomly assigning them to receive either MRD-driven ibrutinib-venetoclax therapy or standard FCR. After a median follow-up of 43.7 months ...

It is still dwarfed by J&J and AbbVie's blockbuster though, which made around $8.4 billion in 2020 from half a dozen indications, including CLL and other blood cancers as well as chronic graft ...